Severe coronavirus disease 2019 causes multi-organ dysfunction with significant morbidity and mortality. Mounting evidence implicates maladaptive over-activation of innate immune pathways such as the complement cascade as well as endothelial dysfunction as significant contributors to disease progression. We review the complement pathways, the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on these pathways, and promising therapeutic targets in clinical trials.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Complement inhibitor, lectin pathway, Complement pathway, mannose-associated serine protease inhibitor, 【초록키워드】 coronavirus disease, coronavirus, multi-organ dysfunction, clinical trials, complement, Endothelial dysfunction, Disease progression, morbidity and mortality, Evidence, Pathways, therapeutic target, acute respiratory syndrome, cascade, Effect, cause, complement pathways, innate immune pathway, Mounting, 【제목키워드】 targeting,
【저자키워드】 COVID-19, SARS-CoV-2, Complement inhibitor, lectin pathway, Complement pathway, mannose-associated serine protease inhibitor, 【초록키워드】 coronavirus disease, coronavirus, multi-organ dysfunction, clinical trials, complement, Endothelial dysfunction, Disease progression, morbidity and mortality, Evidence, Pathways, therapeutic target, acute respiratory syndrome, cascade, Effect, cause, complement pathways, innate immune pathway, Mounting, 【제목키워드】 targeting,